Corbus Pharmaceuticals Announces $15 Million Registered

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Corbus Pharmaceuticals Announces $15 Million Registered Direct Offering

NORWOOD, MA --(Marketwired - June 10, 2016) - Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ : CRBP ) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the Company has entered into a Securities Purchase Agreement for the sale of shares of its common stock in a registered direct offering to investors, including several healthcare oriented fundamental institutional investors. The Company is selling 5,960,000 shares at a purchase price of $2.50 per share with gross proceeds to the Company totaling $14.9 million.

The proceeds from the offering will be used towards the continued advancement of the Company's clinical development programs of its investigational drug, Resunab for the treatment of cystic fibrosis ("CF"), diffuse cutaneous systemic sclerosis ("systemic sclerosis"), skin predominant dermatomyositis and systemic lupus erythematosus ("SLE").

The closing of the offering is expected to take place on or about June 15, 2016, subject to the satisfaction of customary closing conditions.

The shares are being offered by Corbus pursuant to a shelf registration statement on Form S-3 (File No. 333-207936) which was declared effective on November 19, 2015 by the Securities and Exchange Commission (the "SEC"). A prospectus supplement and accompanying base prospectus relating to the offering of the shares will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov . Copies of the prospectus supplement and the accompanying base prospectus relating to the securities may also be obtained from Corbus Pharmaceuticals Holdings, Inc., 100 River Ridge Drive, Norwood, MA 02062.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities are being be offered only by means of a prospectus, including a prospectus supplement and accompanying base prospectus, forming a part of the effective registration statement.

About Resunab

Resunab is a novel synthetic oral endocannabinoid-mimetic drug that preferentially binds to the CB2 receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis. Preclinical and Phase 1 studies have shown Resunab to have a favorable safety, tolerability and pharmacokinetic profile. It has also demonstrated promising potency in preclinical models of inflammation and fibrosis. Resunab is designed to trigger the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of pro-inflammatory eicosanoids and cytokines. Resunab has direct effects on fibroblasts to halt tissue scarring. In effect, Resunab triggers endogenous pathways to turn "off" chronic inflammation and fibrotic processes, without causing immunosuppression.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Our lead product candidate, Resunab, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation, and fibrotic processes. Resunab is currently in Phase 2 clinical studies for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis, skin-predominant dermatomyositis and systemic lupus erythematosus.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter , LinkedIn , Google+ and Facebook .

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the closing of the offering, the use of the proceeds from the offering and the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact Jenene Thomas Jenene Thomas Communications, LLC Phone: +1 (908) 938-1475 Email: jenene@jenenethomascommunications.com Media Contact David Schull Russo Partners, LLC Phone: +1 (858) 717-2310 Email: david.schull@russopartnersllc.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 122

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 491

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 307

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 20

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 74

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 207

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 75

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 58

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 160

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 14

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading

Top 5 Most Recently Viewed Articles

Genius Group Takes Center Stage at Major Investor Events

Updated Category News Views 214

Genius Group Highlights Major Sponsorships in 2025 Genius Group Limited (NYSE: GNS), an AI-driven education enterprise that prioritizes Bitcoin, has announced its participation in two pivotal investor summits. These events provide a significant platform for the company to engage with institutional investors and emphasize its innovative approach to digital assets. Engaging...

Continue Reading
Miami International Holdings Celebrates Robust Q3 Growth

Updated Category News Views 172

Miami International Holdings Reports Strong Financial Performance Miami International Holdings, Inc. (MIH) (NYSE: MIAX) has recently announced impressive financial outcomes for its third quarter, highlighting a remarkable growth trend. The financial data unveiled reflects the organization's ability to thrive in a highly competitive landscape. With a net revenue increase...

Continue Reading
Market Insights: Momo Crowd and GM's Tariff Burdens

Updated Category News Views 382

Understanding Momo Crowd Dynamics in Today's Market The stock market consistently reflects a myriad of influences, one of which is the behavior of retail investors, commonly referred to as the 'momo crowd.' Recent analyses indicate that the actions of these investors can significantly shape market trends, especially during times of heightened volatility. The Cautionary...

Continue Reading
Cathie Wood Praises Shopify: The Future of AI in Retail Awaits

Updated Category News Views 129

Cathie Wood's Enthusiastic Endorsement of Shopify ARK Invest, led by the visionary Cathie Wood, has recently expressed considerable confidence in Shopify Inc. SHOP. This faith stems from the company's forward-thinking approach toward artificial intelligence, particularly their dedicated focus on what they call 'agentic AI'. As the retail landscape evolves, many investors...

Continue Reading
Liftoff IPO: What’s the Real Play Behind the Curtain?

Updated Category News Views 244

Liftoff Mobile's been in the game since day one—on February 17, 2026, they dropped a bombshell, submitting their draft registration statement for an initial public offering (IPO) with the SEC. But hold your horses: nobody knows how many shares will float or what price range they’re angling for. That vagueness? Classic Wall Street move to stir up speculation while...

Continue Reading